Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's Subjects

This study has been completed.
Sponsor:
Collaborator:
Quintiles
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT00360568
First received: August 3, 2006
Last updated: January 12, 2015
Last verified: January 2015
  Purpose

Long term safety and efficacy (12 months) of levodopa-carbidopa intestinal gel.


Condition Intervention Phase
Dyskinesias
Parkinson's Disease
Severe Motor Fluctuations
Drug: Levodopa-carbidopa intestinal gel
Device: CADD-Legacy® 1400 ambulatory infusion pump
Device: PEG tube
Device: J-tube
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Open-Label, 12-Month Safety and Efficacy Study of Levodopa - Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths and Discontinuations Due to AEs [ Time Frame: From study enrollment to the end of study or early termination of treatment, including the removal of PEG-J, plus 30 days. ] [ Designated as safety issue: Yes ]
    AE=any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. SAE=any untoward medical occurrence that: results in death; is life-threatening (an event in which the subject was at risk of death at the time of the event); requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical events. Treatment-emergent events (TEAE or TESAE)=those starting after the first dose of study drug. Severe=severity reported as 'severe' or missing. Possibly or Probably Treatment Related=drug-event relationship reported as 'possible', 'probable' or missing. Death=a fatal outcome of an SAE or AE.

  • Number of Participants With Device Complications [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Complications of the infusion device were collected. Pump, intestinal tube, PEG, stoma, and other complications included (but were not limited to) device breakage, device leakage, device malfunction, device misuse, device occlusion, intentional and unintentional device removal by participant, complication of device insertion, device dislocation, device breakage, device dislocation, and device site reaction.

  • Number of Participants With Potentially Clinically Significant Values for Hematology Parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Terms abbreviated in the table include females (f) and males (m).

  • Number of Participants With Potentially Clinically Significant Values for Clinical Chemistry Parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Terms abbreviated in the table include upper limit of normal (ULN), male (m), and female (f).

  • Number of Participants With Potentially Clinically Significant Vital Sign Parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Terms abbreviated in the table include supine systolic blood pressure (SuSBP), standing systolic blood pressure (StSBP), orthostatic systolic blood pressure (OSBP), supine diastolic blood pressure (SuDBP), standing diastolic blood pressure (StDBP), orthostatic diastolic blood pressure (ODBP), supine pulse (SuP) in beats per minute (bpm), standing pulse (StP), and body temperature (Temp). Increase and decrease are signified by ↑ and ↓, respectively.

  • Number of Participants With Potentially Clinically Significant Electrocardiogram (ECG) Parameters [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Terms abbreviated in the table include heart rate (HR) in beats per minute (bpm), PR interval (PRI), QT interval corrected for heart rate using Bazett's formula (QTcB), and QT interval corrected for heart rate using Fridericia's formula (QTcF). Increase and decrease are signified by ↑ and ↓, respectively.

  • Number of Participants With Sleep Attacks at Baseline and Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: Yes ]
    To prospectively monitor for the possible development of sleep attacks, participants were asked if they had experienced any events in which they fell asleep suddenly or unexpectedly, including while engaged in some activity (e.g., eating/drinking, speaking, or driving) or at rest, with or without any previous warning of sleepiness.

  • Summary of Minnesota Impulsive Disorder Interview (MIDI) Assessment of Intense Impulsive Behavior at Baseline (BL) and Post-baseline (PBL) [ Time Frame: Baseline, Post-baseline (up to Month 12) ] [ Designated as safety issue: Yes ]
    The MIDI is a validated assessment of impulsive behavior consisting of a semistructured clinical interview assessing pathological gambling, trichotillomania (compulsive hair-pulling), kleptomania (compulsive stealing), pyromania (compulsive fire-setting), intermittent explosive disorder, compulsive buying, and compulsive sexual behavior.

  • Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: Yes ]
    The AIMS is an investigator-completed rating scale that has a total of 12 items rating involuntary movements of various areas of the participant's body. Items 1 through 10 are rated on a 5-point scale of severity from 0 (none), 1 (minimal), 2 (mild), 3 (moderate), to 4 (severe), and items 11 and 12 are yes/no questions concerning problems with teeth or dentures. The total AIMS score was calculated by summing items 1-10, with a possible range of 0-40; a negative change indicates improvement. The AIMS was to be performed at consistent times, when the subject was experiencing his/her worst "On" time (dyskinesia [involuntary muscle movement]).

  • Number of Participants With Confirmed Cases of Melanoma [ Time Frame: up to Month 12 ] [ Designated as safety issue: Yes ]
    A comprehensive assessment for the presence of melanoma was performed during the screening period and at early termination/end of study by a dermatologist experienced with the diagnosis of the condition. If a suspicious lesion was present, a biopsy was obtained for proper diagnosis.

  • Number of Participants With Clinically Significant Neurological Examination Findings [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    The neurologic examination was to be done during "On" time. The neurological examination assessed: cranial nerves - assessment of cranial nerves II - XII, excluding fundoscopic examination; motor system - assessment of tone, strength, and abnormal movements; sensory system - including light touch, pinprick, joint position, and vibratory sense; reflexes - assessment of deep tendon reflexes and plantar responses (Babinski sign); coordination - assessment of upper and lower extremities; gait - assessment of base and tandem gait; station - assessment of posture and stability.

  • Columbia-Suicide Severity Rating Scale (C-SSRS) Findings [ Time Frame: up to 12 months ] [ Designated as safety issue: Yes ]
    The Columbia-Suicide Severity Rating Scale (C-SSRS) is a systematically administered instrument developed to track suicidal adverse events across a treatment study. The instrument is designed to assess suicidal behavior and ideation, track and assess all suicidal events, as well as the lethality of attempts. Suicidal ideation categories include the following: wish to be dead; nonspecific active suicidal thoughts; active suicidal ideation without intent to act; active suicidal ideation with some intent to act but no plan; active suicidal ideation with plan and intent. Suicidal behavior categories include the following: actual attempt; interrupted attempt; aborted attempt; preparatory acts or behavior; suicidal behavior; completed suicide.

  • Number of Participants Taking at Least 1 Concomitant Medication During the Study [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
    Concomitant medications include medications started on or after the first open-label LCIG infusion as well as medications started prior to the first open-label infusion but continued during the study.


Secondary Outcome Measures:
  • Change From Baseline in Average Daily "Off" Time at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Negative change from baseline for "off" time indicates improvement.

  • Change From Baseline in Average Daily Normalized "On" Time With Troublesome Dyskinesia at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis.

  • Change From Baseline in Average Daily "On" Time Without Troublesome Dyskinesia at Month 12 [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    Based on the Parkinson's Disease Symptom Diary. "On" time is when PD symptoms are well controlled by the drug. "Off" time is when PD symptoms are not adequately controlled by the drug. "On" time without troublesome dyskinesia (involuntary muscle movement) is defined as "on" time without dyskinesia and "on" time with non-troublesome dyskinesia. The diary is completed every 30 minutes for the full 24 hours of each of 3 days prior to selected clinic visits. It reflects both time awake and time asleep. Daily totals are normalized to a 16-hour scale (i.e. 16 hours of awake time). The normalized totals for the 3 days prior to the visit are averaged for the analysis. Positive change from Baseline for "on" time without troublesome dyskinesia indicates improvement.

  • Clinical Global Impression - Status (CGI-S) Score at Baseline and Clinical Global Impression - Improvement (CGI-I) Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The CGI-S is a global assessment by the Investigator of current symptomatology and impact of illness on functioning. The ratings of the CGI-S are as follows: 1 = normal, 2 = borderline ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, and 7 = among the most extremely ill. The CGI-I is a global assessment by the Investigator of the change in clinical status since the start of treatment. The CGI-I ratings are as follows: 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse.

  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part I Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part I Score is the sum of the answers to the 4 questions that comprise Part I, each of which are measured on a 5-point scale (0-4). The Part I score ranges from 0-16 and higher scores are associated with more disability.

  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part II Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part II score is the sum of the answers to the 13 questions that comprise Part II, each of which are measured on a 5-point scale (0-4). The Part II score ranges from 0-52 and higher scores are associated with more disability.

  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part III score is the sum of the 27 answers provided to the 14 Part III questions, each of which are measured on a 5-point scale (0-4). The Part III score ranges from 0-108 and higher scores are associated with more disability.

  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Total Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The total score is the sum of the responses to the 31 questions (44 answers) that comprise Parts I-III of the scale. The total score will range from 0-176, with 176 representing the worst (total) disability, and 0 representing no disability.

  • Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part IV Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The UPDRS is an Investigator-used rating tool to follow the longitudinal course of Parkinson's disease. The Part IV Score is the sum of the answers to the 11 questions that comprise Part IV, each of which are measured on a 5-point scale (0-4) or a 2-point scale (0 or 1). The Part IV score ranges from 0-23 and higher scores are associated with more disability.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Summary Index at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. These include: mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort. The PDQ-39 Summary Index is the sum of all answers divided by the highest score possible (i.e. number of answers multiplied by 4) which is multiplied by 100 to put the score on a 0-100 scale. Higher scores are associated with more severe symptoms.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Mobility Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Mobility (e.g., fear of falling when walking) includes 10 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Activities of Daily Living Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Activities of Daily Living (e.g., difficulty cutting food) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Emotional Well-Being Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Emotional Well-being (e.g., feelings of isolation) includes 6 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Stigma Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Stigma (e.g., social embarrassment) consists of 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Social Support Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Social Support includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Cognition Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Cognition includes 4 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Communication Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Communication includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in Parkinson's Disease Questionnaire (PDQ-39) Bodily Discomfort Domain Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The PDQ-39 is a self-administered questionnaire which comprises 39 items addressing 8 domains of health in Parkinson's disease patients. The PDQ-39 Domain: Bodily Discomfort includes 3 questions, each answered on a 5-point scale. The domain scores are calculated by first summing the answers to the questions in the domain. The sum is divided by the highest score possible (i.e., number of answers multiplied by 4) and the quotient is multiplied by 100 to put the score on a scale from 0 to 100, where lower scores indicate a better perceived health status. Higher scores are consistently associated with the more severe symptoms of the disease such as tremor and stiffness.

  • Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Summary Index at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The EQ-5D is a participant answered questionnaire scoring 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. EQ-5D health states, defined by the EQ-5D descriptive system, are converted into a single summary index by applying a formula that essentially attaches values (also called QOL weights or QOL utilities) to each of the levels in each dimension. EQ-5D Summary Index values range from -0.11 to 1.00 with positive change indicating improvement.

  • Change From Baseline in EuroQol Quality of Life Scale (EQ-5D) Visual Analogue Scale (VAS) at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 or last post-baseline visit) ] [ Designated as safety issue: No ]
    The EQ-5D VAS records the participant's self-rated health on a scale from 0-100 where 100 is the 'best imaginable health state' and 0 is the 'worst imaginable health state.'

  • Change From Baseline in Zarit Burden Interview (ZBI) Total Score at Endpoint [ Time Frame: Baseline, Endpoint (Month 12 months or last post-baseline visit) ] [ Designated as safety issue: No ]
    The ZBI is a 22-item questionnaire regarding the caregiver/subject relationship and evaluates the caregiver's health condition, psychological well-being, finances and social life. Each question is answered on a 5-point scale (0=never, 1=rarely, 2=sometimes, 3=quite frequently, and 4=nearly always). The caregiver burden is evaluated by the total score (range 0 to 88) obtained from the sum of the answers to the 22 questions. Higher scores are associated with a higher level of burden for the caregiver.


Enrollment: 62
Study Start Date: June 2009
Study Completion Date: October 2012
Primary Completion Date: October 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Levodopa-Carbidopa Intestinal Gel (LCIG)

All participants received LCIG, delivered through a percutaneous endoscopic gastrostomy with jejunal extension (PEG-J), administered for up to 12 months (52 weeks).

Starting dose of LCIG was based on the participant's optimized oral levodopa-carbidopa dose that the subject was receiving just prior to randomization in Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387), administered in the morning of the first day following Study Day 86 of either of these 2 previous studies. The LCIG infusion was expected to infuse over approximately16 hours each day with a rate of infusion within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances.

Drug: Levodopa-carbidopa intestinal gel
Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
Device: CADD-Legacy® 1400 ambulatory infusion pump Device: PEG tube
percutaneous endoscopic gastrostomy tube
Device: J-tube
jejunal tube

Detailed Description:

Study S187.3.003 (NCT00360568) is a Phase 3, 12-month, open-label, multicenter continuation treatment study of the safety, tolerability, and efficacy of levodopa-carbidopa intestinal gel (LCIG) in the treatment of participants with levodopa-responsive Parkinson's disease (PD) with persistent motor fluctuations despite optimized treatment with available PD medications. All participants received LCIG.

Only participants who completed 12 weeks of double-blind, double-dummy treatment in Study S187.3.001 or S187.3.002 (NCT00357994/ NCT00660387) qualified for enrollment in this 12-month continuation treatment study.

  Eligibility

Ages Eligible for Study:   30 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Idiopathic Parkinson's disease (PD) according to United Kingdon Parkinson's Disease Society (UKPDS) Brain Bank Criteria
  • Levodopa-responsive with severe motor fluctuations
  • Completion of protocol S187.3.001 (NCT00357994) or S187.3.002 (NCT00660387) and continue to meet the inclusion criteria for the preceding study

Exclusion Criteria:

  • Patients with medically relevant abnormal findings (labs, electrocardiogram [ECG], physical examination, adverse events, psychiatric, neurological or behavioral disorders, etc.) at end of the double-blind phase (Week 12) of Study S187.3.001 (NCT00357994) or Study S187.3.002 (NCT00660387)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00360568

Locations
United States, Alabama
Site Reference ID/Investigator# 45869
Birmingham, Alabama, United States, 35222
United States, California
Site Reference ID/Investigator# 45834
Fountain Valley, California, United States, 92708
Site Reference ID/Investigator# 45854
Los Angeles, California, United States, 90033
Site Reference ID/Investigator# 45856
Oceanside, California, United States, 92056
United States, District of Columbia
Site Reference ID/Investigator# 45859
Washington, District of Columbia, United States, 20007
United States, Florida
Site Reference ID/Investigator# 45857
Bradenton, Florida, United States, 34205
Site Reference ID/Investigator# 45863
Gainesville, Florida, United States, 32610
Site Reference ID/Investigator# 45836
Port Charlotte, Florida, United States, 33890
United States, Illinois
Site Reference ID/Investigator# 45874
Chicago, Illinois, United States, 60611
United States, Kentucky
Site Reference ID/Investigator# 45868
Lexington, Kentucky, United States, 40536
United States, Maryland
Site Reference ID/Investigator# 45862
Baltimore, Maryland, United States, 21201
United States, Missouri
Site Reference ID/Investigator# 45861
St. Louis, Missouri, United States, 63110
United States, New York
Site Reference ID/Investigator# 45873
New York, New York, United States, 10032
United States, Ohio
Site Reference ID/Investigator# 45878
Cincinnati, Ohio, United States, 45267
Site Reference ID/Investigator# 45850
Cleveland, Ohio, United States, 44195-0001
United States, Vermont
Site Reference ID/Investigator# 45887
Burlington, Vermont, United States, 05401
Germany
Site Reference ID/Investigator# 45828
Bochum, Germany, 44791
Site Reference ID/Investigator# 45829
Bremerhaven, Germany, 27574
Site Reference ID/Investigator# 45825
Hanover, Germany, 30625
Site Reference ID/Investigator# 54402
Tuebingen, Germany, 72076
New Zealand
Site Reference ID/Investigator# 45884
Auckland, New Zealand, 1010
Site Reference ID/Investigator# 45885
Hamilton, New Zealand, 3204
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Quintiles
Investigators
Study Director: Janet Benesh AbbVie
  More Information

Additional Information:
No publications provided

Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT00360568     History of Changes
Other Study ID Numbers: S187.3.003, 2006-000578-53
Study First Received: August 3, 2006
Results First Received: January 12, 2015
Last Updated: January 12, 2015
Health Authority: United States: Food and Drug Administration
New Zealand: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by AbbVie:
carbidopa
severe motor fluctuations
intestinal gel
levodopa
efficacy
levodopa carbidopa intestinal gel
dyskinesia
Parkinson's Disease
Duodopa
levodopa-carbidopa
DUOPA

Additional relevant MeSH terms:
Parkinson Disease
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Movement Disorders
Nervous System Diseases
Neurodegenerative Diseases
Parkinsonian Disorders
Carbidopa
Carbidopa, levodopa drug combination
Levodopa
Adjuvants, Immunologic
Anti-Dyskinesia Agents
Antiparkinson Agents
Central Nervous System Agents
Dopamine Agents
Dopamine Agonists
Enzyme Inhibitors
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses

ClinicalTrials.gov processed this record on February 27, 2015